TY - JOUR T1 - Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis JF - Journal of Neurology, Neurosurgery & Psychiatry JO - J Neurol Neurosurg Psychiatry SP - 1296 LP - 1304 DO - 10.1136/jnnp-2021-326344 VL - 92 IS - 12 AU - Sophy TF Shih AU - Michelle Anne Farrar AU - Veronica Wiley AU - Georgina Chambers Y1 - 2021/12/01 UR - http://jnnp.bmj.com/content/92/12/1296.abstract N2 - Objective To assess cost-effectiveness of newborn screening (NBS) for spinal muscular atrophy (SMA) and early treatment with nusinersen or onasemnogene abeparvovec (gene therapy), compared with nusinersen without SMA screening.Methods Informed by an Australian state-wide SMA NBS programme, a decision analytical model nested with Markov models was constructed to evaluate costs and quality-adjusted life-years (QALYs) from a societal perspective with sensitivity analyses.Results By treating one presymptomatic SMA infant with nusinersen or gene therapy, an additional 9.93 QALYs were gained over 60 years compared with late treatment in clinically diagnosed SMA. The societal cost was $9.8 million for early nusinersen treatment, $4.4 million for early gene therapy and $4.8 million for late nusinersen treatment. Compared with late nusinersen treatment, early gene therapy would be dominant, gaining 9.93 QALYs while saving $360 000; whereas early nusinersen treatment would result in a discounted incremental cost-effectiveness ratio (ICER) of $507 000/QALY.At a population level, compared with no screening and late treatment with nusinersen, NBS and early gene therapy resulted in 0.00085 QALY gained over 60 years and saving $24 per infant screened (85 QALYs gained and $2.4 million saving per 100 000 infants screened). More than three quarters of simulated ICERs by probability sensitivity analyses showed NBS and gene therapy would be dominant or less than $50 000/QALY, compared with no screening and late nusinersen treatment.Conclusion NBS coupled with gene therapy improves the quality and length of life for infants with SMA and would be considered value-for-money from an Australian clinical and policy context.Data are available upon reasonable request. All data relevant to the study are included in the article. This paper reports the modelling cost-effectiveness with published study results and statistics from the pilot study. Data sources of the model parameters are presented in Table 1. ER -